276 related articles for article (PubMed ID: 19025334)
21. Integrated testing strategies for use in the EU REACH system.
Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
Altern Lab Anim; 2006 Aug; 34(4):407-27. PubMed ID: 16945008
[TBL] [Abstract][Full Text] [Related]
22. Integrated testing strategy (ITS) for bioaccumulation assessment under REACH.
Lombardo A; Roncaglioni A; Benfentati E; Nendza M; Segner H; Fernández A; Kühne R; Franco A; Pauné E; Schüürmann G
Environ Int; 2014 Aug; 69():40-50. PubMed ID: 24806447
[TBL] [Abstract][Full Text] [Related]
23. Current EU regulatory requirements for the assessment of chemicals and cosmetic products: challenges and opportunities for introducing new approach methodologies.
Pistollato F; Madia F; Corvi R; Munn S; Grignard E; Paini A; Worth A; Bal-Price A; Prieto P; Casati S; Berggren E; Bopp SK; Zuang V
Arch Toxicol; 2021 Jun; 95(6):1867-1897. PubMed ID: 33851225
[TBL] [Abstract][Full Text] [Related]
24. Introduction to the EU REACH legislation.
Grindon C; Combes R
Altern Lab Anim; 2006 Mar; 34 Suppl 1():5-10. PubMed ID: 16555955
[TBL] [Abstract][Full Text] [Related]
25. An overall strategy for the testing of chemicals for human hazard and risk assessment under the EU REACH system.
Combes R; Barratt M; Balls M
Altern Lab Anim; 2003; 31(1):7-19. PubMed ID: 16221040
[TBL] [Abstract][Full Text] [Related]
26. FRAME and the Royal Commission on Environmental Pollution: common recommendations for assessing risks posed by chemicals under the EU REACH system.
Combes RD; Dandrea J; Balls M
Altern Lab Anim; 2003 Nov; 31(5):529-35. PubMed ID: 15598178
[TBL] [Abstract][Full Text] [Related]
27. Application of in vitro neurotoxicity testing for regulatory purposes: Symposium III summary and research needs.
Bal-Price AK; Suñol C; Weiss DG; van Vliet E; Westerink RH; Costa LG
Neurotoxicology; 2008 May; 29(3):520-31. PubMed ID: 18417220
[TBL] [Abstract][Full Text] [Related]
28. The way forward in reproductive/developmental toxicity testing.
Spielmann H
Altern Lab Anim; 2009 Dec; 37(6):641-56. PubMed ID: 20105000
[TBL] [Abstract][Full Text] [Related]
29. The integrated acute systemic toxicity project (ACuteTox) for the optimisation and validation of alternative in vitro tests.
Clemedson C; Kolman A; Forsby A
Altern Lab Anim; 2007 Mar; 35(1):33-8. PubMed ID: 17411349
[TBL] [Abstract][Full Text] [Related]
30. ECVAM's activities on computer modelling and integrated testing.
Worth AP
Altern Lab Anim; 2002 Dec; 30 Suppl 2():133-7. PubMed ID: 12513665
[TBL] [Abstract][Full Text] [Related]
31. Integrated testing and intelligent assessment-new challenges under REACH.
Ahlers J; Stock F; Werschkun B
Environ Sci Pollut Res Int; 2008 Oct; 15(7):565-72. PubMed ID: 18818964
[TBL] [Abstract][Full Text] [Related]
32. Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation.
Höfer T; Gerner I; Gundert-Remy U; Liebsch M; Schulte A; Spielmann H; Vogel R; Wettig K
Arch Toxicol; 2004 Oct; 78(10):549-64. PubMed ID: 15170526
[TBL] [Abstract][Full Text] [Related]
33. A critical evaluation of the 2011 ECHA reports on compliance with the REACH and CLP regulations and on the use of alternatives to testing on animals for compliance with the REACH regulation.
Spielmann H; Sauer UG; Mekenyan O
Altern Lab Anim; 2011 Oct; 39(5):481-93. PubMed ID: 22103941
[TBL] [Abstract][Full Text] [Related]
34. In Silico Models for Acute Systemic Toxicity.
Burton J; Worth AP; Tsakovska I; Diukendjieva A
Methods Mol Biol; 2016; 1425():177-200. PubMed ID: 27311468
[TBL] [Abstract][Full Text] [Related]
35. The regulatory acceptance of alternatives in the European Union.
Warbrick EV; Evans PF
Altern Lab Anim; 2004 Jun; 32 Suppl 1B():657-61. PubMed ID: 23581154
[TBL] [Abstract][Full Text] [Related]
36. Ten years of REACH - An animal protection perspective.
Taylor K
Altern Lab Anim; 2018 Dec; 46(6):347-373. PubMed ID: 30657330
[TBL] [Abstract][Full Text] [Related]
37. Inhalation toxicity studies: OECD guidelines in relation to REACH and scientific developments.
Arts JH; Muijser H; Jonker D; van de Sandt JJ; Bos PM; Feron VJ
Exp Toxicol Pathol; 2008 Jun; 60(2-3):125-33. PubMed ID: 18455380
[TBL] [Abstract][Full Text] [Related]
38. How are reproductive toxicity and developmental toxicity addressed in REACH dossiers?
Rovida C; Longo F; Rabbit RR
ALTEX; 2011; 28(4):273-94. PubMed ID: 22130481
[TBL] [Abstract][Full Text] [Related]
39. The use of mechanisms and modes of toxic action in integrated testing strategies: the report and recommendations of a workshop held as part of the European Union OSIRIS Integrated Project.
Vonk JA; Benigni R; Hewitt M; Nendza M; Segner H; van de Meent D; Cronin MT
Altern Lab Anim; 2009 Nov; 37(5):557-71. PubMed ID: 20017584
[TBL] [Abstract][Full Text] [Related]
40. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the transatlantic think tank for toxicology (t(4)).
Rovida C; Hartung T
ALTEX; 2009; 26(3):187-208. PubMed ID: 19907906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
